New User:

Forgot your password?

Stock Market & Financial Investment News

News For ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:48 EDTZIOPOptions with increasing implied volatility
Subscribe for More Information
September 28, 2015
16:04 EDTZIOPIntrexon to collaborate with Ziopharm for graft-versus-host disease
Intrexon (XON) announced it has formed a new exclusive channel collaboration with Ziopharm Oncology (ZIOP) for the treatment and prevention of graft-versus-host disease. The collaboration will focus on addressing the underlying pathologies of GvHD through engineered cell platforms to express and deliver interleukin-2. The companies plan to pursue engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The first approach is infusion of regulatory T cells conditionally expressing IL-2 utilizing Intrexon's proprietary gene control approaches such as its RheoSwitch platform. The second is deployment of orally-delivered microbe-based ActoBiotics therapeutics expressing IL-2 to modulate immune function. Under the terms of the agreement, Intrexon will receive a technology access fee of $10M in cash and reimbursement for all research and development costs. The agreement also provides for equal sharing of operating profits.
07:14 EDTZIOPZIOPHARM names Eagle Pharmaceuticals CEO to board
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use